A key discovery regarding the anti-tumour activity of BETi is that these drugs, including first- and second-generation compounds, silence the expression of MYC in preclinical studies, and it appears that the amplification of MYC family members predicts sensitivity to BETi in multiple tumour types.19,64,66 It was therefore widely predicted that elevated levels of MYC would enhance sensitivity to BETi (Fig. 2). The gene discussed is MYC; the disease is neoplasm.